Page 30 - MemoriaES-Eng

RESEARCH PROGRAMMES

difficulty of the problem being studied, the methods used, studies with very specific scientific

objectives, small case series, and results not validated in independent, external cohorts.

The SP-LC project within the CIBERES CRP aims to produce valid and useful knowl-
edge from specific scientific objectives, avoiding the methodological problems that

have placed in question the results of previous studies. The CRP also proposes, in

addition to using the GCCP-II-IASLC Cohort, to generate a CIBERES Cohort, a case
series of patients diagnosed with LC of squamous or adenocarcinoma cell lineage,

and staged post-resection as I/IIp. Samples will include tumour tissue, non-tumorous
pulmonarytissue,lymphnodesandperipheralblood, apartfromthecollectionof clinico-

pathological characteristics of the patient at the time of treatment and following the evolu-

tion of patients included in the prospective cohort at two and five years following treatment,
with information about disease-free time and survival. This will involve only those hospitals

with a thoracic surgery unit and associated with SEPAR (N = 53).

The CIBERES SP-LC aims to create a cohort of patients diagnosed with LC by screening with

LR-CT. An Early COPD Cohort will be generated in the CIBERES Strategic Project on COPD.
The objective of this work is to clinically and molecularly characterize patients with LC in this

Cohort, to establish links between LC and COPD, and to verify molecular variables that dif-
ferentiate cases identified by screening from cases diagnosed in clinical practice.

1. To identify a set of clinico-molecular variables that improve the prognostic
Aims and and predictive capacity of the TNM staging in LC.

objectives
Analysis of biological and molecular variables that have prognostic and/or predictive
value with respect the therapeutic response, independently of TNM staging, in tumour

samples, pulmonary tissue, lymph nodes and peripheral blood will include:

• Epigenetics, according to the methylation pattern of chosen genes

• Immunohistochemistry, determining alterations of the stroma.

• Analysis of inflammation and oxidative stress, by measuring biomarker levels in

tumour tissue and blood

2. To validate in a population of smokers with COPD screening techniques de-

veloped for the general population, and to validate in the former population
prognostic and predictive clinic-molecular variables.

The specific aims for this population are:

•
To create a high-performance cost-effective screening methodology for stage I/
IIp LC.

• To identify biological and molecular variables with potential prognostic and/or pre-

dictive value independently of the pathological TNM, in samples of tumour tis-
13
sue, non-tumour lung tissue, lymph nodes and peripheral blood from patients with 20
squamous/adenocarcinoma-type NSCLC, identified by a screening programme.
T
R
• To identify biological variables associated with the early diagnosis of NSCLC by PO
E
screening (Early-COPD Cohort), compared with the usual care clinical diagnosis L R
A
(GCCP-II-IASLC and CIBERES Cohorts).
NU
N
• To study the potential correlation between the activity of molecular variables for A
COPD and LC.
/
ES
ER
B
CI

30